Which has higher valuation & earnings, GSK or ONC?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.41 $7.54B $3.85 13.32 BeOne Medicines $5.34B 6.30 $286.93M $4.47 68.58

Is GSK or ONC more profitable?

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor GSK or ONC?

In the previous week, BeOne Medicines had 4 more articles in the media than GSK. MarketBeat recorded 14 mentions for BeOne Medicines and 10 mentions for GSK. BeOne Medicines' average media sentiment score of 0.87 beat GSK's score of 0.29 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SNY or ONC?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.12 $8.84B $3.58 12.06 BeOne Medicines $5.34B 6.30 $286.93M $4.47 68.58

Is SNY or ONC more profitable?

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% BeOne Medicines 8.94% 12.06% 6.69%

Does the media prefer SNY or ONC?

In the previous week, BeOne Medicines had 3 more articles in the media than Sanofi. MarketBeat recorded 14 mentions for BeOne Medicines and 11 mentions for Sanofi. BeOne Medicines' average media sentiment score of 0.87 beat Sanofi's score of 0.49 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONC or ARGX more profitable?

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% argenex 31.31% 44.37% 37.55%

Does the media refer more to ONC or ARGX?

In the previous week, BeOne Medicines had 9 more articles in the media than argenex. MarketBeat recorded 14 mentions for BeOne Medicines and 5 mentions for argenex. BeOne Medicines' average media sentiment score of 0.87 beat argenex's score of 0.78 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ONC or TAK?

BeOne Medicines currently has a consensus target price of $390.92, indicating a potential upside of 27.52%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.80 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to ONC or TAK?

In the previous week, BeOne Medicines had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 0.87 beat Takeda Pharmaceutical's score of 0.38 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RVMD or ONC?

In the previous week, BeOne Medicines had 6 more articles in the media than Revolution Medicines. MarketBeat recorded 14 mentions for BeOne Medicines and 8 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.89 beat BeOne Medicines' score of 0.87 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BeOne Medicines (ONC) Competitors

$306.56 +2.60 (+0.86%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$313.57 +7.01 (+2.29%)

As of 07:07 AM Eastern

Compare

ONC vs. GSK, SNY, ARGX, TAK, and RVMD

Should you buy BeOne Medicines stock or one of its competitors? MarketBeat compares BeOne Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeOne Medicines include GSK (GSK), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does BeOne Medicines compare to GSK?

GSK (NYSE:GSK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
BeOne Medicines	8.94%	12.06%	6.69%

15.7% of GSK shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 4 more articles in the media than GSK. MarketBeat recorded 14 mentions for BeOne Medicines and 10 mentions for GSK. BeOne Medicines' average media sentiment score of 0.87 beat GSK's score of 0.29 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.41	$7.54B	$3.85	13.32
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58

GSK currently has a consensus price target of $53.00, indicating a potential upside of 3.37%. BeOne Medicines has a consensus price target of $390.92, indicating a potential upside of 27.52%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

BeOne Medicines beats GSK on 11 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 3 more articles in the media than Sanofi. MarketBeat recorded 14 mentions for BeOne Medicines and 11 mentions for Sanofi. BeOne Medicines' average media sentiment score of 0.87 beat Sanofi's score of 0.49 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BeOne Medicines	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sanofi has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Sanofi presently has a consensus price target of $49.50, suggesting a potential upside of 14.64%. BeOne Medicines has a consensus price target of $390.92, suggesting a potential upside of 27.52%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58

Summary

BeOne Medicines beats Sanofi on 11 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to argenex?

BeOne Medicines (NASDAQ:ONC) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

argenex has lower revenue, but higher earnings than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58
argenex	$4.25B	12.58	$1.29B	$22.46	38.26

BeOne Medicines presently has a consensus price target of $390.92, indicating a potential upside of 27.52%. argenex has a consensus price target of $1,037.61, indicating a potential upside of 20.73%. Given BeOne Medicines' higher probable upside, equities research analysts clearly believe BeOne Medicines is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

In the previous week, BeOne Medicines had 9 more articles in the media than argenex. MarketBeat recorded 14 mentions for BeOne Medicines and 5 mentions for argenex. BeOne Medicines' average media sentiment score of 0.87 beat argenex's score of 0.78 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

BeOne Medicines currently has a consensus target price of $390.92, indicating a potential upside of 27.52%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58
Takeda Pharmaceutical	$28.32B	1.84	-$1.01B	$0.39	42.09

In the previous week, BeOne Medicines had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 0.87 beat Takeda Pharmaceutical's score of 0.38 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Takeda Pharmaceutical's net margin of 4.31%. BeOne Medicines' return on equity of 12.06% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Summary

BeOne Medicines beats Takeda Pharmaceutical on 16 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Revolution Medicines currently has a consensus target price of $144.00, suggesting a potential downside of 22.15%. BeOne Medicines has a consensus target price of $390.92, suggesting a potential upside of 27.52%. Given BeOne Medicines' higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,395.91	-$1.13B	-$7.07	N/A
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58

In the previous week, BeOne Medicines had 6 more articles in the media than Revolution Medicines. MarketBeat recorded 14 mentions for BeOne Medicines and 8 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.89 beat BeOne Medicines' score of 0.87 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Revolution Medicines' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
BeOne Medicines	8.94%	12.06%	6.69%

Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33.35B	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	68.58	18.77	26.96	24.38
Price / Sales	6.30	344.35	518.38	91.92
Price / Cash	77.77	56.83	48.59	59.36
Price / Book	7.71	4.20	10.90	6.33
Net Income	$286.93M	$65.13M	$3.59B	$331.02M
7 Day Performance	1.55%	-2.63%	-1.51%	-0.33%
1 Month Performance	14.30%	2.14%	2.76%	-1.29%
1 Year Performance	13.67%	23.26%	28.54%	21.30%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.674 of 5 stars	$306.56 +0.9%	$390.92 +27.5%	+21.6%	$33.35B	$5.34B	68.58	12,000	News Coverage Analyst Forecast Insider Trade Gap Up
GSK GSK	3.013 of 5 stars	$53.69 +0.1%	$53.00 -1.3%	+33.7%	$108.67B	$43.07B	13.95	66,841	Trending News Dividend Cut
SNY Sanofi	4.1214 of 5 stars	$43.16 flat	$51.00 +18.2%	-11.1%	$104.64B	$49.35B	12.06	74,846
ARGX argenex	4.4893 of 5 stars	$939.68 flat	$1,034.56 +10.1%	+53.1%	$58.44B	$4.25B	41.84	1,863
TAK Takeda Pharmaceutical	1.7359 of 5 stars	$16.74 -0.2%	N/A	+9.2%	$53.37B	$28.32B	42.91	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and RVMD

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to argenex?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and RVMD

How does BeOne Medicines compare to GSK?

Is GSK or ONC more profitable?

Do institutionals & insiders believe in GSK or ONC?

Which has more risk & volatility, GSK or ONC?

Does the media favor GSK or ONC?

Which has higher valuation & earnings, GSK or ONC?

Do analysts prefer GSK or ONC?

Summary

How does BeOne Medicines compare to Sanofi?

Is SNY or ONC more profitable?

Does the media prefer SNY or ONC?

Do insiders and institutionals have more ownership in SNY or ONC?

Which has more volatility and risk, SNY or ONC?

Do analysts rate SNY or ONC?

Which has higher earnings & valuation, SNY or ONC?

Summary

How does BeOne Medicines compare to argenex?

Which has preferable earnings & valuation, ONC or ARGX?

Do analysts prefer ONC or ARGX?

Do institutionals and insiders believe in ONC or ARGX?

Which has more volatility and risk, ONC or ARGX?

Does the media refer more to ONC or ARGX?

Is ONC or ARGX more profitable?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Do analysts recommend ONC or TAK?

Do institutionals & insiders believe in ONC or TAK?

Which has more volatility and risk, ONC or TAK?

Which has preferable valuation and earnings, ONC or TAK?

Does the media refer more to ONC or TAK?

Is ONC or TAK more profitable?

Summary

How does BeOne Medicines compare to Revolution Medicines?

Do analysts recommend RVMD or ONC?

Which has preferable earnings & valuation, RVMD or ONC?

Does the media favor RVMD or ONC?

Is RVMD or ONC more profitable?

Which has more risk & volatility, RVMD or ONC?

Do institutionals and insiders hold more shares of RVMD or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools